版本:
中国

最新动态: 石藥集團有限公司 (1093.HK)

1093.HK ( 香港证券交易所 )

13.84HKD
21 May 2019
涨跌 (%)

HK$-0.02 (-0.14%)
收盘
HK$13.86
开盘
HK$13.86
当日最高
HK$13.96
当日最低
HK$13.64
成交量
19,756,431
平均成交量
36,058,720
52 周最高
HK$26.75
52 周最低
HK$9.90

最新动态 (Source: Significant Developments)

CSPC Pharmaceutical Group Posts Qtrly Profit Attributable Of RMB951.8 Mln
12:05 BJT 

May 21 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::QTRLY PROFIT ATTRIBUTABLE RMB951.8 MILLION VERSUS RMB738.8 MILLION .QTRLY TOTAL REVENUE RMB5.49 BILLION VERSUS RMB4.37 BILLION .  全文

CSPC Pharmaceutical Group Posts FY Profit Attributable Of HK$3.65 Bln
2019年 3月 18日 星期一 12:01 BJT 

March 18 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::FY PROFIT ATTRIBUTABLE HK$3.65 BILLION VERSUS HK$2.77 BILLION.FY REVENUE HK$21.03 BILLION VERSUS HK$15.46 BILLION.DECLARED A FINAL DIVIDEND PER SHARE OF HK18 CENTS.  全文

CSPC Pharmaceutical Submitted New Drug Application To U.S. FDA For Levoamlodipine Maleate Tablets
2019年 3月 5日 星期二 17:58 BJT 

March 5 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::SUBMITTED NEW DRUG APPLICATION TO U.S. FDA FOR LEVOAMLODIPINE MALEATE TABLETS FOR TREATMENT OF HYPERTENSION.  全文

CSPC Pharmaceutical Says Cetrain Financial Media Reported Co Indicated 20 Pct-30 Pct Profit Growth For FY19
2019年 1月 10日 星期四 19:22 BJT 

Jan 10 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::CSPC PHARMACEUTICAL SAYS CETRAIN FINANCIAL MEDIA REPORTED THAT COMPANY INDICATED A TARGET GUIDANCE OF 20%-30% PROFIT GROWTH OF GROUP FOR FY 2019.BOARD STATES THAT ANALYST REPORTS FAIRLY REFLECT CURRENT VIEW OF MANAGEMENT.  全文

CSPC Pharmaceutical Group'S Unit Enters Agreement With I-Mab Biopharma (Shanghai) Co
2018年 12月 17日 星期一 17:18 BJT 

Dec 17 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::UNIT ENTERED INTO AN AGREEMENT WITH I-MAB BIOPHARMA (SHANGHAI) CO., LTD..CSPC BAIKE AGREED TO PAY UPFRONT PAYMENT OF RMB15 MILLION & DEVELOPMENT MILESTONE PAYMENTS OF UP TO RMB135 MILLION TO I-MAB.DEAL FOR LICENSING & COMMERCIALIZATION OF LONG-ACTING RECOMBINANT GLP-1 FC FUSION PROTEIN (TG103) FOR INJECTION DEVELOPED BY I-MAB.  全文

CSPC Pharmaceutical Group's "Amoxicillin Capsules" Granted Approval By NMPA
2018年 11月 26日 星期一 17:02 BJT 

Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::GROUP'S "AMOXICILLIN CAPSULES" GRANTED APPROVAL BY NMPA FOR PASSING CONSISTENCY EVALUATION.  全文

Cspc Pharmaceutical Group Says "Tirofiban Hydrochloride And Sodium Chloride Injection" Granted Drug Registration Approval
2018年 11月 26日 星期一 17:00 BJT 

Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::"TIROFIBAN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" GRANTED DRUG REGISTRATION APPROVAL.APPROVAL GRANTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA.  全文

Cspc Pharmaceutical Group Says Product Candidate "Almb-0166" Granted Orphan-Drug Designation By U.S. FDA
2018年 11月 26日 星期一 16:58 BJT 

Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::GROUP'S PRODUCT CANDIDATE "ALMB-0166" GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA.  全文

CSPC Pharmaceutical Group Posts 9-Mth Profit Attributable Of HK$2.73 Bln
2018年 11月 19日 星期一 12:02 BJT 

Nov 19 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::9-MONTH PROFIT ATTRIBUTABLE TO SHAREHOLDERS HK$2.73 BILLION VERSUS HK$2.04 BILLION.9-MONTH TOTAL REVENUE HK$15.85 BILLION VERSUS HK$11.21 BILLION.  全文

Cspc Pharmaceutical Enters License Deal With Sinocelltech For Anti-CD20 Monoclonal Antibody
2018年 10月 8日 星期一 12:02 BJT 

Oct 8 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::ENTERS DEAL WITH SINOCELLTECH TO LICENSE AND COMMERCIALIZE ANTI- CD20 MONOCLONAL ANTIBODY FOR INJECTION DEVELOPED BY SINOCELLTECH.CO TO PAY SINOCELLTECH UPFRONT & DEVELOPMENT MILESTONE PAYMENTS OF UP TO RMB650 MILLION.PURSUANT TO DEAL, CO WILL BE GRANTED EXCLUSIVE RIGHT FOR PRODUCT BY SINOCELLTECH TO APPLY FOR PRODUCT APPROVAL IN CHINA.  全文